Author:
Spain L.,Walls G.,Julve M.,O’Meara K.,Schmid T.,Kalaitzaki E.,Turajlic S.,Gore M.,Rees J.,Larkin J.
Funder
National Institute for Health Research Royal Marsden Hospital and Institute of Cancer Research Biomedical Research Centre
CRUK
NIHR
Reference17 articles.
1. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015
2. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial;Weber;Lancet Oncol,2015
3. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial;Ribas;Lancet Oncol,2015
4. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med,2011
5. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015
Cited by
221 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献